ACTRN12623001237673
Not Yet Recruiting
Phase 2
Assessment of the effect of Empagliflozin on sympathetic tone and extra-renal effects in anuric haemodialysis patients using microneurography
Dobney Hypertension Centre0 sites20 target enrollmentNovember 30, 2023
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dobney Hypertension Centre
- Enrollment
- 20
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults 18 years and older
- •Anuric haemodialysis patients
- •Able to mobilise independently
- •BP \<160/90 mmHg
Exclusion Criteria
- •Patients with Type 1 Diabetes
- •Patients on SGLT2\-inhbitors prior to the study will be excluded.
- •History of Unilateral or Bilateral Nephrectomy, chronic liver disease, heart failure \[New York Heart Association (NYHA) class II\-IV}, or secondary hypertension
- •Pregnancy (females of childbearing potential must have negative pregnancy test)
- •Relative or absolute contraindication to empagliflozin, including active urinary or genital tract infection, or known drug allergy
- •Severe peripheral vascular disease or neuropathy
- •Initiation of alpha\-blockers, beta\-blockers or moxonidine within the preceding 6 weeks
- •Cardiovascular event(s) within the last 6 months
- •Unstable psychiatric condition or inability to understand and attend appointments
- •On medications such as corticosteroids, multiple antidepressants, and antipsychotics
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
Recruiting
Phase 2
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgeryAtrial fibrillation after heart surgery.Paroxysmal atrial fibrillationIRCT20120520009801N9Mashhad University of Medical Sciences160